Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 45Neoplasm Metastasis 11Pancreatic Neoplasms 8Inflammatory Breast Neoplasms 7Breast Neoplasms, Male 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Neoplasms 4Lung Neoplasms 4Carcinoma, Ductal, Breast 4Sarcoma 3Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Hodgkin Disease 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Thrombocytosis 1Stages II-III Breast Cancer 1Primary Myelofibrosis 1

Interventions

lenvatinib 1camrelizumab 1apatinib 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Triple Negative Breast Cancer × Albumin-Bound Paclitaxel × Breast × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡